Evidence map›Paper›PMID 36441765›Full record

ArticlePLoS neglected tropical diseases2022

Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors.

Stephanie M LaVergne, Saori Sakabe, Mambu Momoh, Lansana Kanneh, Nell Bond, Robert F Garry, Donald S Grant, Juan Carlos de la Torre, Michael B A Oldstone, John S Schieffelin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Decoding the human CD4Cell reports. Medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Robust polyfunctional CD8The Journal of general virology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Lassa Fever Natural History and Clinical Management.Current topics in microbiology and immunology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Stephanie M LaVergneViral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research, San Diego, California, United States of America.ORCID 0000-0001-5902-1154
Saori SakabeViral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research, San Diego, California, United States of America.
Mambu MomohViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Lansana KannehViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Nell BondDepartment of Immunology and Microbiology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Robert F GarryDepartment of Immunology and Microbiology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Juan Carlos de la TorreViral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research, San Diego, California, United States of America.
Michael B A OldstoneViral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research, San Diego, California, United States of America.
John S SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Brian M SullivanViral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research, San Diego, California, United States of America.
Scripps Health · USTulane University · USUniversity of Sierra Leone · SLLa Jolla Institute for Immunology · US

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura D. Hughes · 2018 to 2026
$32.0M
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus DiseaseR01AI123535 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISCHER, WILLIAM, WOHL, DAVID A · 2017 to 2021
$3.3M
NIAID NIH HHS HHSN272201400048CNIAID NIH HHS R01 AI123535NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

introductionLassa virus is a priority pathogen for vaccine research and development, however the duration of cellular immunity and protection in Lassa fever (LF) survivors remains unclear.

methodsWe investigated Lassa virus specific CD8+ T cell responses in 93 LF survivors. Peripheral blood mononuclear cells from these individuals were infected with recombinant vesicular stomatitis virus encoding Lassa virus antigens and virus specific T cell responses were measured after 18-hour incubation. Participants who had undetectable CD8+ T cell response underwent further analysis using a 10-day T cell proliferation assays to evaluate for low T cell precursor frequency.

resultsForty-five of the 93 LF survivors did not have a Lassa virus specific CD8+ T cell response. Of those with responses and a known date of onset of LF (N = 11), 9 had LF within the last ten years. Most participants without a measurable CD8+ T cell response were more than 10 years removed from a clinical history of LF (N = 14/16). Fourteen of 21 patients (67%) with undetectable CD8+ T cell response had a measurable Lassa virus specific CD8+ T cell response with the 10-day assay. DISCUSSION: Despite reports of strong CD8+ T cell responses during acute Lassa virus infection, circulating Lassa virus-specific CD8+ T cells declined to undetectable levels in most Lassa fever survivors after ten years when evaluated with an 18-hour T cell stimulation. However, when Lassa virus-specific T cells were expanded prior to restimulation, a Lassa virus-specific CD8+ T cell response could be detected in many if the samples that were negative in the 18-hour stimulation assay, suggesting that prolonged cellular immunity does exist in Lassa fever survivors at low frequencies.

Indexed as

Lassa FeverPrecursor Cells, T-LymphoidCD8-Positive T-LymphocytesHumansImmunityLassa virusLeukocytes, Mononuclear

Identifiers

PMID36441765
PMCPMC9731491
OpenAlexW4310089609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.